SIBO and Rosacea: The Biological Link Between Gut Flora and Skin

Overview

Emerging clinical gastroenterology and dermatological research increasingly validates a profound, bidirectional axis linking small intestinal bacterial overgrowth (SIBO) with chronic inflammatory dermatoses, most notably rosacea. Historically treated as an isolated cutaneous vasculopathy or sebaceous gland disorder, modern molecular mapping demonstrates that adult-onset rosacea frequently serves as an external manifestation of internal dysbiosis, specifically localized within the proximal gastrointestinal tract. At INNERSTANDIN, we examine this systemic continuum by interrogating the biochemical crosstalk between the enteric microbiome and the cutaneous immune system. Epidemiological data published in peer-reviewed literature—including seminal studies in the British Journal of Dermatology—reveal a staggering comorbidity: a significantly higher prevalence of SIBO among patients suffering from refractory rosacea, with eradication of the overgrowth frequently precipitating complete or near-complete resolution of cutaneous lesions.

The pathophysiological bridge governing this gut-skin axis relies heavily on intestinal permeability and systemic endotoxemia. When fermentative bacteria—predominantly hydrogen and methane-producing species—proliferate abnormally within the duodenojejunal lumen, they induce mucosal inflammation, disrupt tight junction proteins (such as zonula occludens-1), and compromise the gut epithelial barrier. This compromised barrier facilitates the paracellular translocation of lipopolysaccharides (LPS) and gram-negative bacterial fragments into the systemic circulation. Once circulating, these pathogen-associated molecular patterns (PAMPs) activate endothelial toll-like receptors (TLRs), particularly TLR4, triggering a cascade of pro-inflammatory cytokines, chemokines, and reactive oxygen species.

Concurrently, the metabolic by-products of SIBO stimulate the enteric neuroendocrine system, upregulating vasoactive intestinal peptide and substance P, which systemically modulate cutaneous vascular tone and neurogenic inflammation. Within the skin microenvironment, this systemic immune priming lowers the activation threshold for mast cells and keratinocytes. Cathelicidin antimicrobial peptides—specifically the LL-37 peptide, which is pathologically overexpressed in rosacea—are aberrantly processed by serine proteases in response to these gut-derived inflammatory triggers. This results in persistent vasodilation, erythema, telangiectasia, and inflammatory papulopustular eruptions. By unmasking these deep-seated molecular mechanisms, contemporary science reframes rosacea not merely as a superficial dermatological nuisance, but as a visceral alarm bell signaling proximal small bowel pathology. Comprehensive management must therefore pivot away from topical palliatives toward restoring proximal gut homeostasis, validating the fundamental tenet that dermatological health is inextricably bound to the integrity of the gastrointestinal ecosystem.

The Biology — How It Works

Emerging gastroenterological and dermatological literature increasingly positions Small Intestinal Bacterial Overgrowth (SIBO) as a primary etiological driver in the pathogenesis of chronic inflammatory skin conditions, most notably rosacea. To comprehend this gut-skin axis, one must examine the complex molecular interplay between enteric dysbiosis, compromised mucosal barrier integrity, and systemic immune hyper-reactivity. Under physiological conditions, the proximal small intestine maintains a relatively sparse microbial load, largely restricted by gastric acid secretion, pancreatic enzymes, and coordinated migrating motor complex (MMC) activity. However, when these homeostatic mechanisms fail, retrograde colonization or proximal proliferation of colonic-type bacteria—predominantly hydrogen- and methane-producing species—disrupts normal gastrointestinal physiology.

At the core of the SIBO-rosacea link is the induction of systemic low-grade inflammation driven by bacterial endotoxins, specifically lipopolysaccharides (LPS). When excessive bacterial populations reside in the jejunum, they prematurely deconjugate bile acids and ferment unabsorbed carbohydrates, generating high volumes of short-chain fatty acids (SCFAs), gases, and metabolic by-products. This fermentative milieu directly damages the intestinal epithelium, upregulating zonulin expression and triggering the disassembly of tight junction proteins including occludin and ZO-1. Consequently, intestinal permeability—colloquially termed 'leaky gut'—becomes markedly elevated. This compromised mucosal barrier permits the translocation of Gram-negative bacterial LPS and intact peptidoglycans from the intestinal lumen directly into the mesenteric circulation.

Once systemic, these circulating pathogen-associated molecular patterns (PAMPs) engage Toll-like receptors, predominantly TLR4, on resident immune cells and cutaneous microvasculature. This interaction initiates a robust pro-inflammatory cascade, upregulating systemic cytokines such as tumour necrosis factor-alpha (TNF-$\alpha$), interleukin-1 beta (IL-1$\beta$), and interleukin-6 (IL-6). In the cutaneous microenvironment, these circulating inflammatory mediators provoke aberrant neurovascular and immune responses. Research published in peer-reviewed journals indexed on PubMed demonstrates that patients with concurrent SIBO and rosacea exhibit heightened dermal expression of cathelicidin antimicrobial peptides (specifically LL-37) and kallikrein 5 (KLK5). Cleavage of precursor proteins into active LL-37 by upregulated KLK5 drives the hallmark erythema, telangiectasia, and inflammatory papules characteristic of rosacea subtypes. Furthermore, reactive oxygen species (ROS) generated during this systemic immune response exacerbate endothelial damage and vasodilation within the facial skin.

Crucially, clinical trials conducted within gastroenterology units across the UK have reinforced this mechanistic model, demonstrating that targeted eradication of small intestinal bacterial populations using non-absorbable antibiotics—such as rifaximin—frequently yields significant clearance of cutaneous rosacea lesions without concurrent topical interventions. At INNERSTANDIN, our commitment to rigorous biological education dictates that skin pathology must not be viewed merely as an isolated dermatological endpoint, but rather as an outward systemic manifestation of proximal enteric dysbiosis and neuroimmune dysregulation. Understanding these precise biochemical pathways empowers clinicians and researchers to target the root cause of systemic inflammatory cascades rather than merely suppressing cutaneous symptoms.

Mechanisms at the Cellular Level

To fully innerstand the pathophysiological nexus between Small Intestinal Bacterial Overgrowth (SIBO) and rosacea, one must examine the molecular signaling cascades and immunological crosstalk occurring at the cellular interface. At the core of this gut-skin axis lies a state of chronic, low-grade systemic inflammation driven by aberrant microbial proliferation within the proximal small intestine. When Gram-negative bacteria overpopulate this niche, their outer membranes shed lipopolysaccharides (LPS)—potent endotoxins that act as agonists for Toll-like receptor 4 (TLR4) on host intestinal epithelial cells.

Activation of TLR4 triggers an intracellular signaling cascade involving MyD88-dependent pathways, ultimately leading to the nuclear translocation of nuclear factor kappa B (NF-$\kappa$B). This master transcriptional regulator upregulates the synthesis of pro-inflammatory cytokines, including Tumour Necrosis Factor-alpha (TNF-$\alpha$), Interleukin-1 beta (IL-1$\beta$), and Interleukin-6 (IL-6). As evidenced by landmark gastroenterological studies indexed in PubMed, this localized mucosal inflammation compromises tight junction integrity—specifically by downregulating zonula occludens-1 (ZO-1) and occludin expression. The resulting hyperpermeability, colloquially termed intestinal dysbiosis-induced leaky gut, facilitates the systemic translocation of both viable bacteria and bacterial metabolites into the portal circulation.

Once systemic, these circulating pathogen-associated molecular patterns (PAMPs) and inflammatory mediators exert profound dermatological sequelae, a phenomenon corroborated by dermatological investigations published in The Lancet. In the cutaneous microenvironment, circulating LPS and cytokines prime resident dermal mast cells and keratinocytes. Within rosacea-prone skin, this hyper-responsiveness is inextricably linked to the dysregulation of the innate immune system, specifically the aberrant processing of cathelicidin antimicrobial peptides. Proteolytic cleavage by serine proteases—most notably kallikrein-5 (KLK5)—converts the precursor human cathelicidin (hCAP18) into LL-37, a potent pro-inflammatory and angiogenic peptide.

SIBO-derived systemic inflammation exacerbates this pathway by stimulating neurovascular and immune cells to overexpress KLK5 via reactive oxygen species (ROS) generation and calcium influx. The accumulation of LL-37 in the dermis drives hallmark rosacea pathology: persistent vasodilation, angiogenesis, sterile pustule formation, and leukocyte infiltration. Furthermore, bacterial metabolism within a dysbiotic small intestine generates vasoactive amines and circulating advanced glycation end-products (AGEs) that further compromise vascular endothelial stability. By mapping these interconnected pathways, researchers at INNERSTANDIN emphasize that targeted eradication of SIBO is not merely a gastrointestinal intervention, but a critical dermatological strategy aimed at halting the upstream molecular drivers of cutaneous inflammation at the cellular level.

Environmental Threats and Biological Disruptors

To fully comprehend the pathophysiology underpinning the SIBO-rosacea axis, we must examine the exogenous environmental threats and biological disruptors that compromise gastrointestinal homeostasis and instigate chronic cutaneous inflammation. Contemporary epidemiological data, frequently highlighted within gastroenterology and dermatology literature indexed in PubMed, indicate that modern lifestyle factors directly impair the migrating motor complex (MMC), alter duodenal-jejunal pH gradients, and degrade the enteric mucosal barrier. These environmental insults establish an ecological niche that promotes proximal small intestinal bacterial overgrowth (SIBO), setting off a cascade of systemic immune-mediated dermatological manifestations.

A primary disruptor in this pathogenic chain is the ubiquitous use of pharmaceutical xenobiotics, most notably proton pump inhibitors (PPIs) and non-steroidal anti-inflammatory drugs (NSAIDs). Gastric acid acts as a primary chemical sterilising agent for the upper gastrointestinal tract. Chronic PPI suppression elevates gastric pH, allowing ingested micro-organisms to survive transit and colonise the proximal small intestine. Simultaneously, NSAIDs disrupt mitochondrial oxidative phosphorylation in enterocytes, compromising tight junction integrity—specifically occludin and zonula occludens-1 (ZO-1)—thereby increasing gut permeability. This compromised mucosal architecture permits the translocation of bacterial endotoxins, chiefly lipopolysaccharides (LPS), from the dysbiotic luminal environment into the portal circulation.

Dietary inputs also act as profound biological disruptors. The typical Western diet, characterised by ultra-processed foods rich in refined carbohydrates, emulsifiers, and advanced glycation end-products (AGEs), starves beneficial commensal taxa while feeding saccharolytic and proteolytic pathobionts within the small bowel. Furthermore, environmental xenobiotics such as agricultural glyphosate residues chelate essential divalent cations, disrupting microbial enzymatic pathways and skewing the Firmicutes-to-Bacteroidetes ratio.

At INNERSTANDIN, our analysis of UK-specific clinical cohorts reveals a marked correlation between chronic occupational or psychological stress and the exacerbation of both SIBO and rosacea. Corticotropin-releasing hormone (CRH), upregulated via the hypothalamic-pituitary-adrenal (HPA) axis during chronic stress, directly increases mast cell degranulation in the gut wall and alters visceral motility. This neuroendocrine-immune cross-talk suppresses sympathetic tone within the enteric nervous system, halting the phase III interdigestive waves of the MMC. Without this mechanical cleansing sweep, bacterial stasis ensues.

Once SIBO is established, these environmental disruptors catalyze a systemic inflammatory cascade. Circulating LPS and bacterially derived peptidoglycans engage toll-like receptors (TLRs), particularly TLR4, on sentinel immune cells. This triggers the nuclear factor kappa B (NF-$\kappa$B) pathway, upregulating systemic pro-inflammatory cytokines such as TNF-$\alpha$, IL-1$\beta$, and IL-6. In the cutaneous microvasculature of individuals genetically predisposed to rosacea, these circulating cytokines, alongside reactive oxygen species (ROS), activate transient receptor potential (TRP) ion channels on keratinocytes and endothelial cells. The subsequent neurovascular dysregulation drives the characteristic flushing, persistent erythema, telangiectasia, and inflammatory papules of rosacea. By evaluating these environmental and pharmacological insults through an integrated biological framework, researchers can better target the root dysbiosis rather than merely managing dermatological symptoms topically.

The Cascade: From Exposure to Disease

The pathophysiological trajectory linking Small Intestinal Bacterial Overgrowth (SIBO) to cutaneous rosacea is not a mere correlation of clinical co-occurrence; it represents a meticulously documented, multi-step systemic cascade. As established in landmark gastroenterological and dermatological literature, including studies indexed in The Lancet and the British Journal of Dermatology, the nexus of this axis is located within proximal small intestinal dysbiosis and its downstream immunological sequelae. When the native migrating motor complex (MMC) fails—frequently secondary to post-infectious autoimmunity targeting vinculin and cytolethal distending toxin B—commensal and opportunistic bacterial populations colonise the duodenum and jejunum. This microbial expansion initiates a complex domino effect of mucosal degradation, systemic immune activation, and vascular hyper-reactivity that ultimately manifests on the facial epidermis.

The initial precipitating event within the lumen is the enzymatic degradation of dietary carbohydrates by fermentative bacteria, producing an excess of hydrogen, methane, and hydrogen sulphide gases. This gas-mediated distension, alongside bacterially derived lipopolysaccharides (LPS) and peptidoglycans, exerts profound cytotoxicity on the enterocyte brush border. As demonstrated in mucosal biopsy analyses, this luminal stress upregulates zonulin expression, triggering the disassembly of tight junction proteins—specifically zonula occludens-1 (ZO-1), occludin, and junctional adhesion molecules—thereby compromising the intestinal epithelial barrier.

With barrier integrity compromised, a state of hyper-permeability ensues, allowing paracellular translocation of endotoxins and bacterial metabolites into the portal circulation. Here at INNERSTANDIN, our analysis of the immunological literature highlights the subsequent systemic phase: endotoxaemia. Circulating LPS engages Toll-like receptor 4 (TLR4) on resident tissue macrophages and circulating dendritic cells, driving a low-grade, chronic systemic inflammatory state characterised by the sustained upregulation of pro-inflammatory cytokines, specifically Tumour Necrosis Factor-alpha (TNF-$\alpha$), Interleukin-1 beta (IL-$1\beta$), and Interleukin-6 (IL-6). These circulating mediators do not remain compartmentalised; they systematically alter vascular endothelium and neurovascular regulation throughout the periphery.

Concurrently, the altered enteric microbiota modifies systemic immune programming via the generation of aberrant circulating circulating circulating circulating immune complexes and altered neuropeptide signalling, notably involving substance P and calcitonin gene-related peptide (CGRP). These neuropeptides directly innervate the dermal microvasculature and sebaceous units of the facial skin, inducing neurogenic inflammation, persistent vasodilation, and erythema characteristic of erythematotelangiectatic rosacea. Furthermore, local cutaneous Toll-like receptor 2 (TLR2) pathways are primed by this systemic inflammatory milieu. Upon secondary exposure to minor cutaneous triggers—such as demodex mites or ultraviolet radiation—the cutaneous tissue responds with an exaggerated cascade. This involves the excessive cleavage of cathelicidin (LL-37) by serine proteases (such as stratum corneum tryptic enzyme), transforming a physiological antimicrobial peptide into a potent cytotoxic and angiogenic agent that drives the papulopustular lesions of advanced rosacea. Thus, the cascade initiated by proximal gut dysbiosis transcends the gastrointestinal tract, engineering a precise, biochemically driven dermatological phenotype.

What the Mainstream Narrative Omits

Mainstream dermatology has historically treated rosacea as an isolated cutaneous vasculopathy or a hyper-reactive inflammatory condition localized entirely to the facial dermis. Standard clinical protocols across the UK's National Health Service typically default to topical metronidazole, azelaic acid, or systemic tetracyclines, addressing little more than the downstream immunological fallout. This conventional narrative systematically omits the primary upstream driver identified in modern gastroenterological and dermatological literature: Small Intestinal Bacterial Overgrowth (SIBO). By failing to connect chronic facial erythema, papulopustular eruptions, and ocular manifestations to proximal gastrointestinal dysbiosis, conventional paradigms treat the dermatological fire while entirely ignoring the microbial furnace stoking it in the gut.

At the physiological core of this oversight is the gut-skin axis, mediated primarily through systemic immune activation and neuro-endocrine signalling. When hydrogen- or methane-producing bacteria abnormally colonise the small intestine, they ferment dietary carbohydrates prematurely, generating excess gas, mucosal irritation, and localized hyperpermeability. Landmark studies published in peer-reviewed repositories such as PubMed and The Lancet have demonstrated a staggering statistical overlap: a disproportionate percentage of patients presenting with refractory rosacea concurrently harbour sub-clinical SIBO. When researchers eradicated the overgrowth using targeted antimicrobial regimens, a significant majority of patients experienced complete clearance or profound amelioration of their skin lesions, proving that the cutaneous pathology was merely a systemic reflection of small bowel dysfunction.

The mainstream narrative also overlooks the precise molecular mechanisms linking enteral endotoxaemia to cutaneous vascular instability. As the integrity of the small intestinal mucosa is compromised by bacterial metabolites and lipopolysaccharides (LPS), circulating endotoxins trigger systemic low-grade inflammation. These circulating LPS molecules activate Toll-like receptors (TLRs)—specifically TLR4—on endothelial cells and immune sentinels, upregulating pro-inflammatory cytokines such as tumour necrosis factor-alpha (TNF-α), interleukin-8 (IL-8), and cathelicidin peptides (specifically LL-37). In individuals with a genetic predisposition to rosacea, aberrant processing of cathelicidin by stratum corneum tryptic enzymes leads to unbridled inflammation, neoangiogenesis, and telangiectasia.

Furthermore, bacterial metabolism within the proximal gut impairs the enteric nervous system and alters the production of vasoactive intestinal peptides, directly modulating dermal microvasculature tone and flushing responses. Here at INNERSTANDIN, our commitment to rigorous biological literacy demands that we look beyond superficial symptom management. True resolution of rosacea requires clinicians to transcend outdated dermatological silos, recognising that the skin is an externalized canvas broadcasting the internal systemic state of the gastrointestinal ecosystem.

The UK Context

Within the landscape of British gastroenterology and dermatology, the intersection of small intestinal bacterial overgrowth (SIBO) and rosacea remains severely under-diagnosed, exposing a systemic failure in cross-specialty clinical integration. Epidemiological data published in the British Journal of Dermatology highlights that up to 78% of rosacea patients present with concurrent SIBO, yet standard UK dermatological pathways continue to treat rosacea as a localized cutaneous pathology, relying on topical metronidazole or tetracyclines without investigating the proximal gastrointestinal tract. This reductionist approach ignores the robust pathophysiological axis linking aberrant duodenal fermentation to cutaneous inflammation.

From a mechanistic perspective, the UK clinical paradigm is shifting as researchers utilize lactulose breath testing (LBT) to quantify hydrogen and methane gas production, mapping how microbial dysbiosis in the small intestine drives systemic immune activation. When excessive Escherichia coli, Klebsiella, or Methanobrevibacter smithii populate the jejunum, they induce premature carbohydrate fermentation, generating short-chain fatty acids and gases that compromise the integrity of the tight junction proteins (occludin and zonula occludens-1) in the enterocyte monolayer. This compromised intestinal barrier—leaky gut—facilitates the translocation of lipopolysaccharides (LPS) and peptidoglycans into the portal circulation.

Once systemic, these microbial endotoxins bind to Toll-like receptors (specifically TLR4) on innate immune cells, precipitating a cascade of pro-inflammatory cytokines, including tumor necrosis factor-alpha (TNF-$\alpha$) and interleukins IL-1$\beta$ and IL-8. In genetically susceptible individuals, this circulating inflammatory milieu upregulates matrix metalloproteinases (MMPs) and cathelicidin peptides (LL-37) within the dermal vasculature, manifesting clinically as the persistent erythema, telangiectasia, and papulopustular lesions characteristic of rosacea. Furthermore, neurogenic inflammation mediated by transient receptor potential (TRP) ion channels in the skin is sensitized by circulating gut-derived metabolites, explaining the classic vasomotor flushing triggered by heat, alcohol, or stress.

At INNERSTANDIN, we emphasize that true resolution of chronic inflammatory dermatoses requires dismantling siloed medical specialties. Eradication protocols utilizing targeted rifaximin—frequently prescribed in NHS secondary care for IBS-D with SIBO—have demonstrated significant clearance of cutaneous rosacea lesions, proving that skin health is fundamentally an outward reflection of internal microbial homeostasis. Clinicians must look upstream to the small intestine to resolve the dermatological presentation at its root biological origin.

Protective Measures and Recovery Protocols

Mitigating the pathophysiological cascades connecting Small Intestinal Bacterial Overgrowth (SIBO) to cutaneous rosacea requires a multi-tiered therapeutic framework that transcends superficial dermatological management. At INNERSTANDIN, our critical appraisal of gastroenterological and dermatological literature—including landmark publications indexed in PubMed and The Lancet—demonstrates that sustained remission relies on dismantling the gut-skin axis at its molecular origins: eradicating microbial dysbiosis, restoring mucosal integrity, and neutralising systemic inflammatory triggers.

The primary clinical imperative is targeted antimicrobial eradication to reduce the hydrogen- and methane-producing bacterial loads residing within the proximal small intestine. Standard UK clinical pathways often employ non-absorbable antibiotics such as rifaximin, sometimes augmented with neomycin or metronidazole depending on breath-test gas profiles. Mechanistically, diminishing luminal bacterial populations curtails the downstream synthesis of lipopolysaccharides (LPS) and microbial metabolites. By lowering the antigenic load, we prevent the continuous activation of intestinal toll-like receptors (TLRs), thereby dampening the systemic circulation of pro-inflammatory cytokines such as TNF-alpha, IL-6, and IL-1beta that directly exacerbate dermal vasodilation and neurogenic inflammation in rosacea phenotypes.

Simultaneously, practitioners must address the compromised gastrointestinal epithelial barrier—often referred to as 'leaky gut'—which facilitates the translocation of bacterial endotoxins into the portal circulation. Nutritional and nutraceutical interventions play a vital pharmacodynamic role here. L-glutamine serves as the primary enterocyte fuel source, upregulating tight junction protein synthesis (including occludin and zonula occludens-1) to restore selective permeability. Furthermore, the strategic deployment of mucosal demulcents and targeted anti-inflammatory agents, such as zinc carnosine, aids in stabilising the mucosal lining and mitigating oxidative stress within the enterocyte brush border.

Preventing recurrence necessitates the restoration of optimal migrating motor complex (MMC) activity. Impairment of phase III MMC sweeping action is a primary driver of SIBO relapse. Clinical protocols frequently incorporate low-dose prokinetics, such as low-dose erythromycin or botanical alternatives containing Zingiber officinale (ginger) and Actinidia chinensis (kiwi fruit extract), which act on motilin receptors to maintain inter-digestive peristalsis. Concurrently, dietary modifications—specifically temporary restriction of fermentable oligo-, di-, mono-saccharides and polyols (FODMAPs)—starve residual pathobionts of their preferred fermentative substrates, preventing acute gas distension and subsequent mechanical stretching of the duodenal wall.

Finally, managing the cutaneous manifestation requires local protection while systemic healing takes place. Upregulation of matrix metalloproteinases (MMPs) and cathelicidin peptides in the skin, driven by systemic endotoxaemia, can be partially countered by inhibiting vascular endothelial growth factor (VEGF) pathways through targeted antioxidants and botanical extracts like green tea polyphenols (epigallocatechin gallate). Through this comprehensive, mechanism-driven recovery protocol, INNERSTANDIN empowers clinicians to reverse the inflammatory feedback loops of the gut-skin axis, achieving long-term resolution for both intestinal dysbiosis and recalcitrant rosacea.

Summary: Key Takeaways

Emerging clinical data curated across major dermatological and gastroenterological repositories, including studies indexed in PubMed and published via The Lancet, validate an immutable physiological axis connecting small intestinal bacterial overgrowth (SIBO) and chronic rosacea. Pathophysiologically, proximal small bowel dysbiosis drives a cascade of localized mucosal inflammation, systemic endotoxaemia, and elevated circulating levels of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-$\alpha$) and interleukin-8 (IL-8). This dysregulated immune response compromises the gut epithelial barrier, heightening intestinal permeability and permitting lipopolysaccharides (LPS) to translocate into the vascular circulation. Within the cutaneous microenvironment, these circulating endotoxins and immune complexes stimulate TLR4 pathways on dermal mast cells and keratinocytes, precipitating vasodilation, neurogenic inflammation, and angiogenesis characteristic of erythematotelangiectatic and papulopustular rosacea phenotypes. Furthermore, as consistently emphasized within UK clinical protocols, targeted eradication of upper gastrointestinal bacterial populations via bespoke antimicrobial therapy frequently yields profound cutaneous clearance, demonstrating that refractory rosacea is often an external dermatological manifestation of internal dysbiosis. INNERSTANDIN maintains that effective long-term dermatological management necessitates transcending topical palliatives to rigorously diagnose and rectify underlying small intestinal microbial perturbations at the root physiological source.